IL-4/IL-13 targeted biologics in atopic dermatitis: is their use safe in oncologic patients?

Expert Opinion on Biological Therapy 2026 Open access

Read full text
Authors: Elena Ippoliti, Luisa Boeti, Alessandra D'Amore, Maria Vittoria Cannizzaro, Ketty Peris, Niccolò Gori
DOI: 10.1080/14712598.2026.2628688
Cited by: 1
References: 14

Abstract

1.0 Dupilumab, a humanized antibody targeting the interleukin-4 receptor alpha (IL-4Rα), together with the interleukin (IL)-13 antagonists, tralokinumab and lebrikizumab, have changed atopic dermat...

Fields of Study & Subjects

Dermatology and Skin Diseases Psoriasis: Treatment and Pathogenesis Asthma and respiratory diseases

Publication details

Journal / source
Expert Opinion on Biological Therapy
Publisher
Informa UK Limited
Volume
26
Issue
2
Pages
99–101
Publication date
1 February 2026
Language
EN